provide additional evidence that it is unlikely that either psoriasis or severe psoriasis is a relevant risk factor for MI. Even if-after accounting for confounding and biaspsoriasis is significantly associated with CVD risk, psoriasis is unlikely to be a clinically useful independent risk factor for CVD.
1. the risk factor should be easily and reliably measured.
Can patients with psoriasis be reliably distinguished from those without psoriasis? Even when assessed by dermatologists, reliable and reproducible diagnostic criteria for mild psoriasis are lacking (Rzany et al., 1997) . A nondermatologist's diagnosis of psoriasis is even less likely to be reliable (i.e., to have high sensitivity and specificity).
Most epidemiologic studies that demonstrated an association of severe psoriasis and CVD used process measures to define severe psoriasis (Gelfand et al., 2006; Friedewald et al., 2008) . Processbased measures of disease severity are particularly vulnerable to bias. Behavioral and socioeconomic factors affect both the process of care and the likelihood an individual will seek care. Therefore, process measures are unlikely to reliably discriminate between patients who, by "objective" clinical criteria, would be considered to have severe psoriasis and those with less severe disease.
There is no reproducible, or even agreed on, clinically or biologically based definition of severe psoriasis. The lack of a good measure to accurately classify an affected person's severity for purposes of CVD risk stratification is further complicated by the variability of an individual's extent and burden of psoriasis over time and the fact that external factors may alter psoriasis "severity." Is a single episode of extensive psoriasis or use of a systemic agent sufficient to classify that patient as severe? Does a person who had a flare of psoriasis after strep tococcal infection, but who otherwise has limited disease, have severe psoriasis? 2. It should be an independent predictor of major cVD events in persons of intermediate risk who have no history of cVD.
Most data suggesting an association between psoriasis and CVD have come from specialized populations at either low or high risk of CVD. The individuals studied often lacked clear or complete histories of CVD. The strongest associations were observed in groups defined post hoc. In Gelfand and colleagues ' JAMA study (2006) , the only strong assoc iation between psoriasis and myocardial infarction (MI) was for young individuals (a post hoc subset analysis) with severe psoriasis (process defined). This highest-relative-risk group (severe psoriasis in patients younger than age 50) had a low baseline risk of MI (<1 in 1,000 per year) and comprised only 1/4,000 of the total population served by study practitioners and 3% of those identified as having psoriasis.
3. When assessed in individuals at intermediate risk, the risk factor should reclassify a substantial portion as high risk.
The associations of intermediate psoriasis with CVD in groups have been weak (relative risk <1.5) and often not significant (Gelfand et al., 2006; Brauchli et al., 2009) . The prevalence of psoriasis in the general population is relatively low (2 to 3%). The prevalence of indiv iduals ident ifiable as having severe psoriasis in population-based studies is very low. The point prevalence of psoriasis involving 10% of the body surface area is less than 1 in 5,000 (Stern et al., 2004) . Therefore, if psoriasis (or severe psoriasis) is utilized as an additional risk factor, the CVD risk category would change for only a few people. Wakkee et al. (2010, this issue) found that when traditional risk factors are considered, having psoriasis does not reclassify MI risk in a substantial number of persons.
reclassified individuals should be managed differently.
At high and increasing frequency, I have received "literature" that suggests biologic therapies for psoriasis may lower CVD risk (Strober and Young, 2009 ). In addition, a company-sponsored study designed to show that etanercept will reduce the inflammation associated with metabolic syndrome and decrease the risk of heart disease in patients with psoriasis treated with etanercept is "under way" (ClinicalTrials.gov, 2007) . Changes in C-reactive protein (CRP) appear to be the primary end point for this study.
CRP is, at best, a relatively moderate predictor of coronary heart disease, with borderline significance (Danesh et al., 2004; Wilson et al., 2005; Melander et al., 2009) . Even if tumor necrosis factor (TNF) blockers lower CRP, it is highly speculative that a lower CRP will be associated with CVD benefits. A recent meta-analysis that assessed this issue concluded, "Sufficient evidence that reducing CRP levels prevents coronary heart disease events is lacking" (Buckley et al., 2009) .
CRP elevation may be more frequent among patients with more extensive psoriasis. However, in a company-sponsored retrospective analysis, etanercept reduced CRP levels in some but not other groups of psoriasis patients (Strober et al., 2008) . Without good evidence that lowering CRP levels (or other mediators or cytokines that biologic agents might decrease) will have a beneficial effect on CVD among persons with severe psoriasis, claims that therapies that reduce CRP level will also lower CVD risk should be viewed with skepticism.
One might be more optimistic about biologics reducing CVD risk if systemic levels (as opposed to skin levels) of a biologic's target, such as TNF-α, were substantially elevated in persons with psoriasis and higher systemic levels of the target were independent predictors of CVD risk. Robust evidence that systemic levels of TNF-α (or other targets of biologics) are substantially elevated in patients with psoriasis, or that systemic levels of these targets are highly associated with psoriasis severity, is lacking. Evidence that higher systemic levels of TNF-α or other targets of biologics are strong independent predictors of coronary heart disease or CVD risk is also lacking (Jefferis et al., 2009) . Therefore, expecting that an agent with a specific target such as TNF-α or IL-12 (neither is a well-established risk factor for CVD) will reduce CVD is at best wishful thinking.
The nonsteroidal anti-inflammatory drug experience with CRP and CVD risk provides a cautionary tale. One year before the withdrawal of rofecoxib because of increased CV risk, a study demonstrated that Cox-2 inhibitors lowered CRP levels and posited that Cox-2 inhibitors might reduce CVD risk (Chenevard et al., 2003) . Clinical trials proved this hypothesis to be very wrong (Waxman, 2005) .
The homocysteine story provides further caution about the validity of the hypothesis that lowering levels of a substance associated with CVD will lower CVD risk. Homocysteine is an established risk factor for cardio vascular disease. Vitamin B supplementation reduces homocysteine levels. Two random ized placebo control trials, enrolling nearly 7,000 patients, showed that vitamin B supplementation reduces homocysteine levels (Bonaa et al., 2006; Ebbing et al., 2008) . However, vitamin B therapy had no effect on the risk of mortality or cardiovascular events. The results of one trial suggested a harmful effect of vitamin B supplementation (Bonaa et al., 2006) . In patients with psoriatic arthritis, a TNF-α inhibitor lowered homocysteine levels but raised triglyceride and apolipoprotein B levels, which could increase CVD risk (Sattar et al., 2007) . Previously, vitamin B had been considered a reasonably innoc uous treatment. The same cannot be said for biologic therapies.
5.
If two or more risk factors provide similar prognostic information, then convenience, cost, and safety may be important in choosing among them.
Neither psoriasis nor severe psoriasis is likely to provide nearly as precise or important prognostic information as traditional risk factors for CVD such as blood pressure, body mass index (obesity), depression, diabetes, smoking, lipid levels, and lack of exercise.
A number of these established CVD risk factors may be more frequent in psoriasis patients (particularly those with severe disease) than in the general population (Naldi et al., 2005) . Therefore, physicians caring for psoriasis patients should assess these established risk factors for cardio vascular disease. If risk factors are present, the clinician should help in their optimal management. Improving a patient's psoriasis is likely to help depression and encourage changes in lifestyle such as smoking cessation, weight loss, and increased exercise, which reduce CVD risk. The consideration of CVD risk reduction as a potential benefit of biologic therapy per se is at best premature, not evidence based, and potentially wrong-headed. Providing good dermatologic care includes being aware of a patient's CVD risk factors and facilitating preventive care and lifestyle changes. Believing that psoriasis or severe psoriasis is a clinically useful independent risk factor for CVD, or that targeted therapies for psoriasis will directly reduce CVD risk, is at best unproven and most likely not the case.
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Wakkee and colleagues (2010, this issue) do not present data on the positive predictive value of their coding algorithm to measure the exposure of interest (psoriasis) or the outcome of interest (hospitalizations for ischemic heart disease (IHD)) using the gold standard of medical-record review. Thus, one cannot exclude misclassification bias as a source of error that explains their negative results. Furthermore, Wakkee et al. did not report the results of their multivariable model, so we are unable to determine whether their approach was able to confirm the expected relationships between cardiovascular (CV) risk factors and hospitalization for acute IHD (von Elm et al., 2007) .
The second basic principle is statistical error. The key question is whether a study has the statistical power to detect a clinically meaningful association, if one truly exists. Wakkee et al. show in Table 2 of their article that the hazard ratios for acute IHD hospitalization (primary end point) and acute myocardial infarction (secondary end point), adjusted for prior use of antihypertensive, antidiabetic, and lipid-lowering
